JAK2 and leukemia: TSLPRCART treatment of a third IGH::CRLF2/JAK2 wild-type DS-ALL PDX model (TCHK150) potently inhibited in vivo leukemia proliferation with impaired T cell functionality with simultaneous ruxolitinib co-administration at day 0.